OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ICO$1.1855

Iconovo AB

Medical Equipment, Supplies & DistributionVerified

Iconovo AB's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.01, suggesting limited short-term liquidity cushion. The price-to-book ratio of 0.96 implies that the market values the company slightly below its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium. Profitability metrics reveal a challenging operating environment for Iconovo AB. The company reported a net loss of -43,363,860 SEK and an operating loss of -43,112,760 SEK, resulting in a negative return on equity of -36.77% and a return on assets of -33.08%. These figures fall significantly below the industry's median profitability metrics, highlighting a need for operational improvements or cost restructuring. Iconovo AB's revenue is concentrated within its core business of medical equipment and supplies, with no disclosed geographic diversification in the provided data. The company's exposure to a single business line increases its vulnerability to sector-specific downturns or supply chain disruptions. No segment-specific revenue breakdown is available in the input data. The company's growth trajectory is currently negative, with a net loss and declining cash flows. The operating cash flow of -31,870,880 SEK and free cash flow of -47,751,660 SEK indicate a cash outflow, which could constrain future growth initiatives. The capital expenditure of -14,089,110 SEK suggests ongoing investment in infrastructure, but the negative cash flow may limit the sustainability of such investments. Risk factors for Iconovo AB include medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no near-term pressure from share issuance. However, the company's negative operating and net income may necessitate future financing, which could introduce dilution risk if not managed carefully. Recent events and filings have not been disclosed in the input data, so no specific recent developments can be cited. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.

30-day price · ICO+0.03 (+2.6%)
Low$1.00High$1.32Close$1.18As of27 May, 00:00 UTC
Profile
CompanyIconovo AB
TickerICO.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Iconovo AB provides medical equipment, supplies, and distribution services within the healthcare sector, primarily generating revenue through the sale and distribution of medical devices and related products.

Classification. Iconovo AB is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Iconovo AB's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.01, suggesting limited short-term liquidity cushion. The price-to-book ratio of 0.96 implies that the market values the company slightly below its book value, while the price-to-tangible-book ratio is identical, indicating no significant intangible asset premium. Profitability metrics reveal a challenging operating environment for Iconovo AB. The company reported a net loss of -43,363,860 SEK and an operating loss of -43,112,760 SEK, resulting in a negative return on equity of -36.77% and a return on assets of -33.08%. These figures fall significantly below the industry's median profitability metrics, highlighting a need for operational improvements or cost restructuring. Iconovo AB's revenue is concentrated within its core business of medical equipment and supplies, with no disclosed geographic diversification in the provided data. The company's exposure to a single business line increases its vulnerability to sector-specific downturns or supply chain disruptions. No segment-specific revenue breakdown is available in the input data. The company's growth trajectory is currently negative, with a net loss and declining cash flows. The operating cash flow of -31,870,880 SEK and free cash flow of -47,751,660 SEK indicate a cash outflow, which could constrain future growth initiatives. The capital expenditure of -14,089,110 SEK suggests ongoing investment in infrastructure, but the negative cash flow may limit the sustainability of such investments. Risk factors for Iconovo AB include medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no near-term pressure from share issuance. However, the company's negative operating and net income may necessitate future financing, which could introduce dilution risk if not managed carefully. Recent events and filings have not been disclosed in the input data, so no specific recent developments can be cited. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.
Key takeaways
  • Iconovo AB operates in the medical equipment and supplies industry with a conservative capital structure.
  • The company is currently unprofitable, with a negative return on equity and assets.
  • Revenue is concentrated in a single business line, increasing vulnerability to sector-specific risks.
  • Liquidity is a medium concern, with limited short-term liquidity cushion.
  • The company's growth trajectory is negative, with declining cash flows and operating losses.
  • Dilution risk is currently low, but future financing needs may introduce dilution pressure.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$1.1M
Gross profit$11.5M
Operating income-$43.1M
Net income-$43.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$31.9M
CapEx-$14.1M
Free cash flow-$47.8M
Total assets$131.1M
Total liabilities$13.2M
Total equity$117.9M
Cash & equivalents
Long-term debt$3.7M
Valuation
Market price$1.18
Market cap$113.0M
Enterprise value$116.7M
P/E
Reported non-GAAP P/E
EV/Revenue105.7
EV/Op income
EV/OCF
P/B1.0
P/Tangible book1.0
Tangible book$117.9M
Net cash-$3.7M
Current ratio1.0
Debt/Equity0.0
ROA-33.1%
ROE-36.8%
Cash conversion73.0%
CapEx/Revenue-12.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricICOActivity
Op margin-3902.8%3.9% medp25 -31.3% · p75 14.4%bottom quartile
Net margin-3925.5%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin1042.6%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-1275.4%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity3.0%17.9% medp25 2.7% · p75 52.2%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-19 17:25 UTC#faa36f84
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 04:31 UTCJob: 2cec0636